View ValuationSNDL 将来の成長Future 基準チェック /06SNDLは、138.4%と3.8%でそれぞれ年率138.4%で利益と収益が成長すると予測される一方、EPSはgrowで58%年率。主要情報138.4%収益成長率57.96%EPS成長率Pharmaceuticals 収益成長31.5%収益成長率3.8%将来の株主資本利益率n/aアナリストカバレッジLow最終更新日30 Apr 2026今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesRecent Insider Transactions • May 03Independent Non-Executive Chairman recently bought CA$95k worth of stockOn the 1st of May, J. Mills bought around 50k shares on-market at roughly CA$1.89 per share. This transaction increased J.'s direct individual holding by 1x at the time of the trade. This was the largest purchase by an insider in the last 3 months. J. has been a buyer over the last 12 months, purchasing a net total of CA$166k worth in shares.Reported Earnings • May 01First quarter 2026 earnings released: CA$0.04 loss per share (vs CA$0.057 loss in 1Q 2025)First quarter 2026 results: CA$0.04 loss per share (improved from CA$0.057 loss in 1Q 2025). Revenue: CA$195.9m (down 4.4% from 1Q 2025). Net loss: CA$9.91m (loss narrowed 33% from 1Q 2025). Revenue is forecast to grow 3.7% p.a. on average during the next 3 years, compared to a 8.9% growth forecast for the Pharmaceuticals industry in Canada.お知らせ • Apr 16SNDL Inc. to Report Q1, 2026 Results on Apr 29, 2026SNDL Inc. announced that they will report Q1, 2026 results Pre-Market on Apr 29, 2026お知らせ • Mar 31SNDL Inc. Announces Executive Changes for Cannabis SegmentSNDL Inc. announced on March 30, 2026 that Tyler Robson, President of Cannabis, has left the Company in order to pursue other opportunities. Ryan Hellard, SNDL’s current Chief Strategy Officer, will assume the role of Interim President of Cannabis. The Company wishes Mr. Robson success in his future endeavours.New Risk • Mar 15New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 13% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 13% per year for the foreseeable future. Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (CA$21m net loss in 2 years).New Risk • Mar 13New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: CA$16m Forecast net loss in 2 years: CA$21m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. This is currently the only risk that has been identified for the company.Reported Earnings • Mar 13Full year 2025 earnings released: CA$0.06 loss per share (vs CA$0.36 loss in FY 2024)Full year 2025 results: CA$0.06 loss per share (improved from CA$0.36 loss in FY 2024). Revenue: CA$946.4m (up 2.8% from FY 2024). Net loss: CA$15.8m (loss narrowed 83% from FY 2024). Revenue is forecast to grow 3.5% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in Canada.お知らせ • Feb 20SNDL Inc. to Report Q4, 2025 Results on Mar 12, 2026SNDL Inc. announced that they will report Q4, 2025 results Pre-Market on Mar 12, 2026Board Change • Feb 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. Independent Director James Cannell was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Nov 22SNDL Inc. (NasdaqCM:SNDL) announces an Equity Buyback for 24,500,000 shares, for CAD 100 million.SNDL Inc. (NasdaqCM:SNDL) announces a share repurchase program. Under the program, the company will repurchase up to 24,500,000 common shares, representing 10% of its issued share capital for CAD 100 million. The purpose of the program is opportunistically return value to shareholders. All shares purchased pursuant to the Share Repurchase Program will be returned to treasury for cancellation. The program is valid till November 20, 2026.New Risk • Nov 17New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: CA$92m Forecast net loss in 1 year: CA$3.8m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. This is currently the only risk that has been identified for the company.Recent Insider Transactions • Nov 10Independent Non-Executive Chairman recently bought CA$72k worth of stockOn the 6th of November, J. Mills bought around 40k shares on-market at roughly CA$1.79 per share. This transaction increased J.'s direct individual holding by 40000x at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was J.'s only on-market trade for the last 12 months.Reported Earnings • Nov 04Third quarter 2025 earnings released: CA$0.05 loss per share (vs CA$0.073 loss in 3Q 2024)Third quarter 2025 results: CA$0.05 loss per share (improved from CA$0.073 loss in 3Q 2024). Revenue: CA$244.2m (up 3.1% from 3Q 2024). Net loss: CA$13.3m (loss narrowed 31% from 3Q 2024). Revenue is forecast to grow 2.8% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in Canada.お知らせ • Oct 16SNDL Inc. to Report Q3, 2025 Results on Nov 04, 2025SNDL Inc. announced that they will report Q3, 2025 results at 9:30 AM, US Eastern Standard Time on Nov 04, 2025Reported Earnings • Aug 01Second quarter 2025 earnings released: EPS: CA$0.01 (vs CA$0.022 loss in 2Q 2024)Second quarter 2025 results: EPS: CA$0.01 (up from CA$0.022 loss in 2Q 2024). Revenue: CA$244.8m (up 7.3% from 2Q 2024). Net income: CA$2.89m (up CA$8.66m from 2Q 2024). Profit margin: 1.2% (up from net loss in 2Q 2024). Revenue is forecast to grow 5.1% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Pharmaceuticals industry in Canada.お知らせ • Jul 11SNDL Inc. to Report Q2, 2025 Results on Jul 31, 2025SNDL Inc. announced that they will report Q2, 2025 results Pre-Market on Jul 31, 2025お知らせ • Jun 23SNDL Inc., Annual General Meeting, Jul 29, 2025SNDL Inc., Annual General Meeting, Jul 29, 2025.New Risk • May 14New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: CA$107m Forecast net loss in 1 year: CA$9.5m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Shares are highly illiquid. Minor Risk Currently unprofitable and not forecast to become profitable next year (CA$9.5m net loss next year).Reported Earnings • May 02First quarter 2025 earnings released: CA$0.06 loss per share (vs CA$0.01 loss in 1Q 2024)First quarter 2025 results: CA$0.06 loss per share (further deteriorated from CA$0.01 loss in 1Q 2024). Revenue: CA$204.9m (up 3.6% from 1Q 2024). Net loss: CA$14.7m (loss widened 476% from 1Q 2024). Revenue is forecast to grow 5.5% p.a. on average during the next 3 years, compared to a 8.6% growth forecast for the Pharmaceuticals industry in Canada.お知らせ • Apr 15SNDL Inc. to Report Q1, 2025 Results on May 01, 2025SNDL Inc. announced that they will report Q1, 2025 results Pre-Market on May 01, 2025業績と収益の成長予測CNSX:SNDL - アナリストの将来予測と過去の財務データ ( )CAD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20281,000N/AN/AN/A112/31/2027951112174212/31/2026922-6287723/31/2026937-115367N/A12/31/2025946-165871N/A9/30/2025952-925870N/A6/30/2025944-985061N/A3/31/2025928-1074959N/A12/31/2024920-954455N/A9/30/2024911-1103444N/A6/30/2024912-1134049N/A3/31/2024916-1362635N/A12/31/2023909-168-25-17N/A9/30/2023901-211-11-1N/A6/30/2023894-287-29-20N/A3/31/2023886-331-41-29N/A12/31/2022712-335-18-7N/A9/30/2022495-266-38-30N/A6/30/2022278-151-101-95N/A3/31/202264-130-152-147N/A12/31/202156-227-160-156N/A9/30/202147-228-176-173N/A6/30/202146-316-140-137N/A3/31/202157-296-80-78N/A12/31/202061-200-61-57N/A9/30/202062-170-123-101N/A6/30/202077-184-157-109N/A3/31/202076-164-189-107N/A12/31/201964-143N/A-113N/A9/30/201949-156N/A-75N/A6/30/201921-84N/A-49N/A3/31/20191-77N/A-49N/A12/31/2018N/A-68N/A-31N/A2/28/2018N/A-13N/A-5N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: SNDL今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: SNDL今後 3 年間、利益が出ない状態が続くと予測されています。高成長収益: SNDL今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: SNDLの収益 ( 3.8% ) Canadian市場 ( 4.5% ) よりも低い成長が予測されています。高い収益成長: SNDLの収益 ( 3.8% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: SNDLの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 05:32終値2026/05/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋SNDL Inc. 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。9 アナリスト機関Aaron GreyAlliance Global PartnersFrederico Yokota Choucair GomesATB CormarkDavid KideckelATB Cormark6 その他のアナリストを表示
Recent Insider Transactions • May 03Independent Non-Executive Chairman recently bought CA$95k worth of stockOn the 1st of May, J. Mills bought around 50k shares on-market at roughly CA$1.89 per share. This transaction increased J.'s direct individual holding by 1x at the time of the trade. This was the largest purchase by an insider in the last 3 months. J. has been a buyer over the last 12 months, purchasing a net total of CA$166k worth in shares.
Reported Earnings • May 01First quarter 2026 earnings released: CA$0.04 loss per share (vs CA$0.057 loss in 1Q 2025)First quarter 2026 results: CA$0.04 loss per share (improved from CA$0.057 loss in 1Q 2025). Revenue: CA$195.9m (down 4.4% from 1Q 2025). Net loss: CA$9.91m (loss narrowed 33% from 1Q 2025). Revenue is forecast to grow 3.7% p.a. on average during the next 3 years, compared to a 8.9% growth forecast for the Pharmaceuticals industry in Canada.
お知らせ • Apr 16SNDL Inc. to Report Q1, 2026 Results on Apr 29, 2026SNDL Inc. announced that they will report Q1, 2026 results Pre-Market on Apr 29, 2026
お知らせ • Mar 31SNDL Inc. Announces Executive Changes for Cannabis SegmentSNDL Inc. announced on March 30, 2026 that Tyler Robson, President of Cannabis, has left the Company in order to pursue other opportunities. Ryan Hellard, SNDL’s current Chief Strategy Officer, will assume the role of Interim President of Cannabis. The Company wishes Mr. Robson success in his future endeavours.
New Risk • Mar 15New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 13% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 13% per year for the foreseeable future. Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (CA$21m net loss in 2 years).
New Risk • Mar 13New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: CA$16m Forecast net loss in 2 years: CA$21m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. This is currently the only risk that has been identified for the company.
Reported Earnings • Mar 13Full year 2025 earnings released: CA$0.06 loss per share (vs CA$0.36 loss in FY 2024)Full year 2025 results: CA$0.06 loss per share (improved from CA$0.36 loss in FY 2024). Revenue: CA$946.4m (up 2.8% from FY 2024). Net loss: CA$15.8m (loss narrowed 83% from FY 2024). Revenue is forecast to grow 3.5% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in Canada.
お知らせ • Feb 20SNDL Inc. to Report Q4, 2025 Results on Mar 12, 2026SNDL Inc. announced that they will report Q4, 2025 results Pre-Market on Mar 12, 2026
Board Change • Feb 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. Independent Director James Cannell was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Nov 22SNDL Inc. (NasdaqCM:SNDL) announces an Equity Buyback for 24,500,000 shares, for CAD 100 million.SNDL Inc. (NasdaqCM:SNDL) announces a share repurchase program. Under the program, the company will repurchase up to 24,500,000 common shares, representing 10% of its issued share capital for CAD 100 million. The purpose of the program is opportunistically return value to shareholders. All shares purchased pursuant to the Share Repurchase Program will be returned to treasury for cancellation. The program is valid till November 20, 2026.
New Risk • Nov 17New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: CA$92m Forecast net loss in 1 year: CA$3.8m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. This is currently the only risk that has been identified for the company.
Recent Insider Transactions • Nov 10Independent Non-Executive Chairman recently bought CA$72k worth of stockOn the 6th of November, J. Mills bought around 40k shares on-market at roughly CA$1.79 per share. This transaction increased J.'s direct individual holding by 40000x at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was J.'s only on-market trade for the last 12 months.
Reported Earnings • Nov 04Third quarter 2025 earnings released: CA$0.05 loss per share (vs CA$0.073 loss in 3Q 2024)Third quarter 2025 results: CA$0.05 loss per share (improved from CA$0.073 loss in 3Q 2024). Revenue: CA$244.2m (up 3.1% from 3Q 2024). Net loss: CA$13.3m (loss narrowed 31% from 3Q 2024). Revenue is forecast to grow 2.8% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in Canada.
お知らせ • Oct 16SNDL Inc. to Report Q3, 2025 Results on Nov 04, 2025SNDL Inc. announced that they will report Q3, 2025 results at 9:30 AM, US Eastern Standard Time on Nov 04, 2025
Reported Earnings • Aug 01Second quarter 2025 earnings released: EPS: CA$0.01 (vs CA$0.022 loss in 2Q 2024)Second quarter 2025 results: EPS: CA$0.01 (up from CA$0.022 loss in 2Q 2024). Revenue: CA$244.8m (up 7.3% from 2Q 2024). Net income: CA$2.89m (up CA$8.66m from 2Q 2024). Profit margin: 1.2% (up from net loss in 2Q 2024). Revenue is forecast to grow 5.1% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Pharmaceuticals industry in Canada.
お知らせ • Jul 11SNDL Inc. to Report Q2, 2025 Results on Jul 31, 2025SNDL Inc. announced that they will report Q2, 2025 results Pre-Market on Jul 31, 2025
お知らせ • Jun 23SNDL Inc., Annual General Meeting, Jul 29, 2025SNDL Inc., Annual General Meeting, Jul 29, 2025.
New Risk • May 14New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: CA$107m Forecast net loss in 1 year: CA$9.5m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Shares are highly illiquid. Minor Risk Currently unprofitable and not forecast to become profitable next year (CA$9.5m net loss next year).
Reported Earnings • May 02First quarter 2025 earnings released: CA$0.06 loss per share (vs CA$0.01 loss in 1Q 2024)First quarter 2025 results: CA$0.06 loss per share (further deteriorated from CA$0.01 loss in 1Q 2024). Revenue: CA$204.9m (up 3.6% from 1Q 2024). Net loss: CA$14.7m (loss widened 476% from 1Q 2024). Revenue is forecast to grow 5.5% p.a. on average during the next 3 years, compared to a 8.6% growth forecast for the Pharmaceuticals industry in Canada.
お知らせ • Apr 15SNDL Inc. to Report Q1, 2025 Results on May 01, 2025SNDL Inc. announced that they will report Q1, 2025 results Pre-Market on May 01, 2025